Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia

Overview of attention for article published in Journal of Cancer Research and Clinical Oncology, January 2001

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

policy: 2 policy sources
patent: 14 patents

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 103 Dimensions

Readers on

mendeley: 32 Mendeley

Summary Policy documents Patents Wikipedia Dimensions citations

So far, Altmetric has seen 4 policy documents that reference this research output.

Treanda for Chronic Lymphocytic Leukemia (Relapsed/ Refractory)

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Treanda for Chronic Lymphocytic Leukemia (First Line)

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 19 Oct 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia: Leukaemia (chronic lymphocytic) - ofatumumab (previously untreated): evaluation report and supporting information

Cited by National Institute for Health and Care Excellence on 03 Nov 2014

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.